Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Age-related Macular Degeneration Market

Age-related Macular Degeneration Market Share

Report ID: GMI12195
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Age-related Macular Degeneration Market Share

The market is characterized by competition, featuring a blend of major global players alongside smaller and medium-sized companies vying for market share. A pivotal strategy in this market revolves around the consistent introduction of innovative products harnessing diverse technologies. Industry giants, wielding significant influence, often spearhead advancements, bolstered by substantial investments in research and development.

Furthermore, maneuvers like strategic alliances, acquisitions, and mergers play a crucial role in fortifying market positions and broadening global reach, especially in the face of shifting regulatory landscapes. Meanwhile, smaller vendors carve out their niche by focusing on specific applications to stand toe-to-toe with established players.

Age-related Macular Degeneration Market Industry News:

In July 2024, Genentech, part of the Roche Group, reintroduced Susvimo (ranibizumab injection) 100 mg/mL via ocular implant for intravitreal use. This treatment targets individuals in the U.S. with wet, or neovascular AMD. The relaunch is poised to boost patient access to effective treatments and enhance adherence by reducing injection frequency.
In September 2021, AbbVie and REGENXBIO Inc. forged a partnership to develop and commercialize RGX-314, a promising one-time gene therapy aimed at wet AMD, diabetic retinopathy (DR), and other chronic retinal ailments. As per the collaboration, AbbVie spearheads the clinical development and global commercialization of RGX-314, while REGENXBIO plays a role in U.S. commercialization efforts.

Age-related Macular Degeneration Market Companies

Some of the eminent market participants operating in the age-related macular degeneration industry include:

Adverum Biotechnologies
Alkeus Pharmaceuticals
Amgen
Astellas Pharma
Bausch Health Companies
Bayer AG
Biogen
Coherus BioSciences
F. Hoffmann-La Roche
Kodiak Sciences
Novartis AG
Pfizer
Regeneron Pharmaceuticals
Sandoz Group AG
STADA Arzneimittel AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global age-related macular degeneration industry was valued at around USD 10.4 billion in 2023 and is estimated to grow at a 9.8% CAGR from 2024 to 2032, driven by the increasing prevalence of AMD among the aging population.

Eylea led the market in 2023, generating substantial revenue of USD 4.4 billion due to its established trust among healthcare providers and patients since its FDA approval in 2011.

The U.S. age-related macular degeneration market was valued at USD 4.2 billion in 2023 and is projected to grow at a CAGR of 9.9% over the forecast period, fueled by the rising population aged 65 and older.

Key players in the market include Adverum Biotechnologies, Alkeus Pharmaceuticals, Amgen, Astellas Pharma, Bausch Health Companies, Bayer AG, Biogen, Coherus BioSciences, F. Hoffmann-La Roche, and Kodiak Sciences.